The results from Chen and colleagues are intriguing and in this study, we have used clinical tissues to evaluate the expression of PLD1 with phospho-Akt and phospho-mTOR in breast carcinomas to help facilitate patient selection for mTOR-targeted therapies. The gene discussed is AKT1; the disease is breast carcinoma.